Comments
Syngene International, a global contract research services company, has entered into an R&D agreement with healthcare major GSK.
The multi-year agreement will focus on accelerating the discovery of new drug candidates using Syngene’s discovery services platform, Sygene said in a statement.
As per this agreement, Syngene will set up a discovery research laboratory to support projects across several therapeutic areas.
Also, a team of Syngene scientists will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs.
Jonathan Hunt, Chief Executive Officer, Syngene International, said: "The collaboration in many ways underlines Syngene’s position as an innovative, capable and cost-effective provider of discovery research services to the global pharma industry.’’
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.